BOCH
ORIC icon

Blue Owl Capital Holdings’s Oric Pharmaceuticals ORIC Stock Holding History

Blue Owl Capital Holdings’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Buy
400,000
+250,000
+167% +$2.27M 0.65% 26
2026
Q1 		$1.9M Sell
150,000
-365,000
-71% -$4.14M 0.51% 32
2025
Q4 		$4.21M Buy
+515,000
New +$5.93M 1.3% 24

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blue Owl Capital Holdings's ORIC Position: Q2 2026 in Review

Blue Owl Capital Holdings increased its Oric Pharmaceuticals (ORIC) stake by 167% in Q2 2026, buying an estimated $2.27M and bringing the position to 400,000 shares worth $4.33M. The position accounts for 0.65% of the portfolio, ranked #26.

Blue Owl Capital Holdings first reported a position in ORIC in Q4 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Blue Owl Capital Holdings held 400,000 shares of Oric Pharmaceuticals worth $4.33M as of Q2 2026.
  • Blue Owl Capital Holdings bought 250,000 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
  • Oric Pharmaceuticals made up 0.65% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #26 holding.
  • Blue Owl Capital Holdings first reported a position in Oric Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.